NIH Will Not “March-In” On Pfizer’s Xalatan
This article was originally published in The Pink Sheet Daily
Executive Summary
Similar to its decision in the Norvir case, NIH says availability, not price, is test of whether the agency can “march-in” on a company’s exclusivity.
You may also be interested in...
Makena Pricing Prompts Multi-Pronged Appeals: FDA, FTC – Bayh-Dole?
The uproar among insurers, physicians and patient groups over the relatively high price of KV Pharmaceutical’s new injectable treatment for preventing preterm births, Makena, has elicited appeals to FDA and the Federal Trade Commission for intervention.
Makena Pricing Prompts Multi-Pronged Appeals: FDA, FTC – Bayh-Dole?
The uproar among insurers, physicians and patient groups over the relatively high price of KV Pharmaceutical’s new injectable treatment for preventing preterm births, Makena, has elicited appeals to FDA and the Federal Trade Commission for intervention.
Patent March-In Power: Government Likes Having, Not Using It
GAO report concludes that although never employed, Bayh-Dole power "is particularly valuable as leverage in informal discussions."